A mid-stage trial of the vaccine in South Africa, where a troubling new variant of the virus is common, showed 60% effectiveness among people who did not have HIV. Novavax shares surged 34% in after hours trading following release of the trial results on the same day the United States reported its first cases of the South African variant.from World News Headlines, Latest International News, World Breaking News - Times of India https://ift.tt/3cnYBQG
Post a Comment